How Germany and Switzerland Are Redefining Global Leadership

By Michael Megarit

In 2025, the global pharmaceutical trade reflects both growth and tension. While Total EU pharmaceutical exports soared 13.5% in 2024 to a record €313.4 billion, geopolitical strains are emerging, particularly in Switzerland’s case. Understanding what drives export powerhouses like Germany and Switzerland reveals strategic openings in CDMO, biotech, and resilient supply chains

Germany: Volume, Scale, and Consistent Growth

Germany’s pharmaceutical exports reached US$126.1 billion in 2024, up from US$115 billion in 2023, cementing its position as the world’s largest exporter.

Trading Economics

Extra-EU exports totaled €67.9 billion in 2024, with the United States as the primary destination.

Strategy in play: Germany leverages economies of scale, robust R&D pipelines, and an established CDMO infrastructure that remains attractive for value-driven partnerships.

Switzerland: Quality, Pricing, and Tariff Resilience

  • Swiss pharmaceutical exports climbed to CHF 149 billion in 2024, a 10% YoY increase, making it a global leader in high-value niches.
  • Despite a U.S. tariff spike to 39%, Switzerland’s pharma exports, worth CHF 32.75 billion annually, remain under scrutiny. Pharmaceutical products are currently exempt, but uncertainty continues to cloud the outlook.
  • Strengths: Premium positioning, advanced biologics, and a readiness by Roche and Novartis to anchor manufacturing in the U.S. (>$73B commitments) to hedge tariff risks.

EU Context: A Record Export Surplus

In 2024, the EU’s pharmaceutical sector posted a trade surplus of €193.6 billion, marking the highest ever tracked.Germany’s extra-EU strength underscores not just national leadership but regional dominance in market reach.

Strategic Implications for Investors

OpportunityRationale    
CDMO Partnerships    Germany’s scalable capacity supports tailored outsourcing, ideal for both regional and global pharma players.    
Biotech Export Niches    Switzerland’s foundation in biologics and premium markets creates high-margin, resilient investment themes.    
Onshore ResilienceTariff risks in Switzerland make U.S. production investments (e.g., Roche, Novartis) strategic lifelines

Germany’s scale and Switzerland’s high-margin specialization continue to shape the global pharma landscape. Export strategies are evolving, and investors must look beyond rankings, into infrastructure, geopolitics, and trade dynamics.

Explore this: Venture Capital and Private Equity: Investment Strategies

Read Our Other Blogs: BLOG